On the public citation graph

Discovery of Cyclopropane Sulfonamide Derivatives As a Potent Inhibitor of Egfr Against Mutation C797s

https://doi.org/10.2139/ssrn.4647254
0 signed · 37 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

1 of the 37 references listed on this page is in the Retraction Watch database as retracted (export 2026-11-11): 10.1158/0008-5472.can-22-0394 (notice 2022-08-26).

Dataset join, best-effort; this page does not check the publisher record. Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0); dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/med.21488openalex-extracted
Targeting EGFR L858R/T790M and EGFR L858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry
inferredcites →https://doi.org/10.1007/978-3-319-91442-8_14openalex-extracted
Afatinib
inferredcites →https://doi.org/10.1016/j.bioorg.2022.105743openalex-extracted
Novel third-generation pyrimidines-based EGFR tyrosine kinase inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
inferredcites →https://doi.org/10.1016/j.ejmech.2022.114900openalex-extracted
Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy
inferredcites →https://doi.org/10.1016/j.jtho.2017.06.006openalex-extracted
Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations
inferredcites →https://doi.org/10.1016/j.lungcan.2019.09.017openalex-extracted
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
inferredcites →https://doi.org/10.1016/j.matbio.2021.02.004openalex-extracted
Causes and consequences of DNA damage-induced autophagy
inferredcites →https://doi.org/10.1016/j.semcancer.2023.05.006openalex-extracted
Current knowledge of small cell lung cancer transformation from non-small cell lung cancer
inferredcites →https://doi.org/10.1016/j.tibs.2021.01.014openalex-extracted
Rapid Detection and Signaling of DNA Damage by PARP-1
inferredcites →https://doi.org/10.1016/j.xcrm.2020.100007openalex-extracted
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
inferredcites →https://doi.org/10.1016/s2213-2600(21)00134-xopenalex-extracted
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
inferredcites →https://doi.org/10.1021/acs.jmedchem.2c00704openalex-extracted
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1021/acs.jmedchem.3c00277openalex-extracted
Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC
inferredcites →https://doi.org/10.1023/a:1008209720526openalex-extracted
Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials
inferredcites →https://doi.org/10.1038/d41586-020-03152-0openalex-extracted
Lung cancer
inferredcites →https://doi.org/10.1038/nature17960openalex-extracted
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
inferredcites →https://doi.org/10.1038/nature25183openalex-extracted
The biology and management of non-small cell lung cancer
inferredcites →https://doi.org/10.1038/nrd1136openalex-extracted
Gefitinib
inferredcites →https://doi.org/10.1038/nrd1445openalex-extracted
Cetuximab
inferredcites →https://doi.org/10.1038/s41419-021-04496-9openalex-extracted
ZC3H15 promotes glioblastoma progression through regulating EGFR stability
inferredcites →https://doi.org/10.1038/s41467-023-35961-yopenalex-extracted
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
inferredcites →https://doi.org/10.1038/s41571-018-0099-7openalex-extracted
Erlotinib effective in the neoadjuvant setting
inferredcites →https://doi.org/10.1038/s41571-022-00639-9openalex-extracted
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
inferredcites →https://doi.org/10.1093/annonc/mdx703openalex-extracted
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
inferredcites →https://doi.org/10.1111/cas.15229openalex-extracted
LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo
inferredcites →https://doi.org/10.1158/0008-5472.can-21-3481openalex-extracted
Antibody–Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.1158/0008-5472.can-22-0394openalex-extracted
The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02–011 Overcomes C797S-Mediated Resistance in Lung Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-0569openalex-extracted
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
inferredcites →https://doi.org/10.1158/1078-0432.ccr-22-3901openalex-extracted
BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.1158/1535-7163.mct-20-0229openalex-extracted
CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation
inferredcites →https://doi.org/10.1158/2159-8290.cd-14-0337openalex-extracted
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
inferredcites →https://doi.org/10.1158/2159-8290.cd-18-0903openalex-extracted
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
inferredcites →https://doi.org/10.1177/1758834017702820openalex-extracted
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
inferredcites →https://doi.org/10.1186/s13045-022-01391-4openalex-extracted
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
inferredcites →https://doi.org/10.1517/13543780902762843openalex-extracted
Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer
inferredcites →https://doi.org/10.3390/cancers10080248openalex-extracted
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
inferredcites →https://doi.org/10.3390/molecules28052006openalex-extracted
Novel Dual-Target Kinase Inhibitors of EGFR and ALK Were Designed, Synthesized, and Induced Cell Apoptosis in Non-Small Cell Lung Cancer
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.